Keywords: hematide, 18-month, hb, maintenance, drug, developer, affymax

Hematide: 18-month Hb maintenance

Article | 14 April 2008

Print This

US drug developer Affymax and Japanese drug major Takeda have reported strong data on their ongoing Phase II trial to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in